Amgen Inc. (NASDAQ: AMGN) announced results from its Phase 3 VESALIUS-CV clinical trial showing that Repatha reduced the risk of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE